Bone appears to act like fertilizer for many tumors, including myeloma and metastatic breast cancer. The explanation must lie in interactions between tumor cells and the bone-tissue microenvironment. At this level, too, must lie the explanation of how bisphosphonates address not only cancer osteolysis but also the tumor burden. By inhibiting osteoclasts, the drugs may block a cancer-related vicious cycle.
No takes yet. Share an insight, caveat, or question.
Gregory R. Mundy (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: